CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy
More about Open Access at the CrickAuthors list
Maëlle Ralu Simon Guiraud Sumitava Dastidar Paola Galbiati Emilia Sadaoui Fetta Mazed Fatima Amor Anne de Cian Isabelle Richard Kamel Mamchaoui Giuseppe Ronzitti Francesco Saverio Tedesco Mario AmendolaAbstract
Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by loss of dystrophin. Upregulating utrophin, a dystrophin paralogue, is a promising gene therapy approach. Here, we present a CRISPR-Cas9-based strategy to enhance utrophin expression by disrupting repressor binding sites. Using a Cas9/gRNA ribonucleoprotein complex we disrupted several such sites in DMD myoblasts and identified micro-RNA Let-7c binding site as effective in relieving repression of the UTRN gene. Interestingly, Cas9-generated indels were as effective as the complete removal of Let-7c binding site in upregulating UTRN expression, with minimal off-target effects. In a three-dimensional tissue-engineered human skeletal muscle model of DMD, this editing strategy resulted in significant utrophin upregulation and functional improvements of calcium dysregulation and muscle contraction. Finally, in mdx mice, local or systemic delivery of recombinant adeno-associated viruses encoding Cas9 and gRNA targeting the Let-7c binding site resulted in utrophin upregulation and amelioration of muscle histopathology and function. These findings provide the foundations for a mutation-independent, potentially universal gene editing therapeutic strategy for DMD.
Journal details
Journal
Molecular Therapy
Volume
34
Issue number
7
Pages
3903-3923
Available online
Publication date
Full text links
Publisher website (DOI)
10.1016/j.ymthe.2026.03.025
Figshare
View on figshare
Europe PubMed Central
41877484
Pubmed
41877484
Keywords
Related topics
Type of publication
Publishing history
The publication was previously a preprint.
View preprint
